← Leaderboards
Alexei V Tumanov
University Of Texas Hlth Science Center
$3,701,018
Attributed
$8,064,733
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2015–24$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,064,733 · 6
By mechanism
R01$6,237,922 · 2
R21$1,826,811 · 4
Top collaborators
- Armen N Akopian9 shared
- Ekaterina Koroleva4 shared
- Shivani B Ruparel4 shared
- Luis Martinez-Sobrido2 shared
- Yan Xiang2 shared
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Man-Kyo Chung$11,589,894
- Ekaterina Koroleva$518,889
- Shivani B Ruparel$4,640,622
- Karen Ann Lindquist$59,252
- Yu Shin Kim$4,018,851
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsImmuneMediatingImmunopathologyInflammationPreventMemberTumor Necrosis Factor ReceptorInnovationLymphotoxin Beta ReceptorEquilibriumComplexPathway InteractionsTumor Necrosis Factor-BetaKidneyImmune ResponseSignal TransductionImmunotherapeutic AgentMaintenanceTranscriptome SequencingTissuesImmunityNovel TherapeuticsTherapeutic Target
Grant awards (18)
Lymphotoxin-Beta Receptor Peripheral Signaling Regulates the Transition to Inflammation and Neuropathy-Induced Chronic Pain$477,522
R01 · FY2024 · NS
Novel animal models to study organ-specific SARS-CoV-2-induced pathology$220,625
R21 · FY2024 · AI · contact PI
Lymphotoxin-Beta Receptor Peripheral Signaling Regulates the Transition to Inflammation and Neuropathy-Induced Chronic Pain$492,291
R01 · FY2023 · NS
Novel animal models to study organ-specific SARS-CoV-2-induced pathology$278,500
R21 · FY2023 · AI · contact PI
Targeting SARS-CoV-2 induced lung immunopathology using novel genetic mouse models$190,161
R21 · FY2023 · AI · contact PI
Lymphotoxin-beta receptor peripheral signaling regulates the transition to inflammation and neuropathy-induced chronic pain$492,291
R01 · FY2022 · NS
Targeting SARS-CoV-2 induced lung immunopathology using novel genetic mouse models$228,911
R21 · FY2022 · AI · contact PI
Lymphotoxin-beta receptor peripheral signaling regulates the transition to inflammation and neuropathy-induced chronic pain$490,967
R01 · FY2021 · NS
LIGHT and Lymphotoxin targeting for the treatment of chronic orofacial pain conditions$140,306
R01 · FY2021 · DE
Lymphotoxin-beta receptor peripheral signaling regulates the transition to inflammation and neuropathy-induced chronic pain$489,115
R01 · FY2020 · NS
LIGHT and Lymphotoxin targeting for the treatment of chronic orofacial pain conditions$231,000
R01 · FY2020 · DE
LIGHT and Lymphotoxin induced modulation of trigeminal ganglia sensory neuron excitability$197,180
R01 · FY2020 · DE
LIGHT and Lymphotoxin targeting for the treatment of chronic orofacial pain conditions$3,227,250
R01 · FY2019 · DE
Innate lymphoid cells in Campylobacter-induced colitis$190,625
R21 · FY2019 · AI · contact PI
Innate lymphoid cells in Campylobacter-induced colitis$228,750
R21 · FY2018 · AI · contact PI
Defining the role of lymphotoxin signaling in viral-induced lung immunopathology$168,688
R21 · FY2016 · AI · contact PI
Defining the role of lymphotoxin signaling in viral-induced lung immunopathology$28,051
R21 · FY2016 · AI · contact PI
Defining the role of lymphotoxin signaling in viral-induced lung immunopathology$292,500
R21 · FY2015 · AI · contact PI